Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
Zijun Wang; Julio C C Lorenzi; Frauke Muecksch; Shlomo Finkin; Charlotte Viant; Christian Gaebler; Melissa Cipolla; Hans-Heinrich Hoffman; Thiago Y Oliveira; Deena A Oren; Victor Ramos; Lilian Nogueira; Eleftherios Michailidis; Davide F Robbiani; Anna Gazumyan; Charles M Rice; Theodora Hatziioannou; Paul D Bieniasz; Marina Caskey; Michel C Nussenzweig.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-288555
SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.
Texto completo
Documentos relacionados